Listed in 2012 with Nasdaq® as AXDX
Global: Tucson, AZ, United States
EMEA: Barcelona, Spain
Accelerate Diagnostics is an in vitro diagnostics company engaged in providing solutions that develops patient outcomes through the diagnosis of serious infections. The Company’s platform, the Accelerate Pheno SystemTM utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST). It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTestTM BC kit provides ID and AST results within 7 hours for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. These fast results will enable clinicians to make targeted, lifesaving therapy decisions 1- 2 days earlier compared with conventional methods.